PDF
ePub
Citation
Print
Abstract
Primary aldosteronism is a syndrome characterized by hypokalemic alkalosis and hypertension. Aldosterone-producing adenomas and bilateral adrenal hyperplasia are common causes of this syndrome. An aldosterone-producing adrenocortical carcinoma is a very rare cause of primary aldosteronism. Recently we experienced a case of an aldosterone-producing adrenocortical carcinoma.
A 41-year-old female was admitted for evaluation of a retroperitoneal mass. Because of hypokalemia and a history of hypertension, we evaluated the patient for primary aldosteronism. The high ratio of plasma aldosterone to renin activity suggested the possibility of the presence of primary aldosteronism. We performed adrenal vein sampling for differential diagnosis of an aldosterone-producing tumor from a retroperitoneal mass. The adrenal vein sampling showed that the primary aldosteronism was due to an aldosterone-producing tumor from the left adrenal gland. Surgical findings indicated that the retroperitoneal mass originated from the left adrenal gland and the pathological diagnosis for the mass was an adrenocortical carcinoma. In conclusion, the results from the adrenal vein sampling, as well as the surgical and pathological findings demonstrate that this case was an aldosterone-producing adrenocortical carcinoma.
Figures and Tables
Fig. 1
Computed tomography of abdomen showed 8.0 cm sized hypervascular mass lesion with multifocal necrosis and cystic portion at retroperitoneum.
Fig. 2
The cut surface of the mass shows pink-gray to yellow-tan solid mass with multifocal hemorrhages, necrosis, calcification, and cystic changes.
References
1. Choi HG, Kim MK, Chung SK, Park YK. An aldosterone secreting adrenal cortical carcinoma. Korean J Urol. 1994. 5(2):194–197.
2. Cho SC, Park YS, Park HG, Lee SH, Kim SG, Choi WH, Ahn YH, Jung PJ, Kim TW. A clinical observation on twelve cases of primary aldosteronism. J Kor Soc Endocrinol. 2004. 19:194–202.
3. Kim YH, Koh SH, Lee SM, Lee KH, Hong SH, Yoon C. Primary aldosteronism. J Korean surg soc. 1999. 56:1031–1037.
4. Seccia TM, Fassina A, Nussdorfer GG, Pessina AC, Rossi GP. Aldosterone-producing adrenocortical carcinoma: an unusual cause of Conn's syndrome with an ominous clinical course. Endocrine-Related Cancer. 2005. 12:149–159.
5. Weinberger MH, Fineberg NS. The diagnosis of primary aldosteronism and separation of two major subtypes. Arch Intern Med. 1993. 153:2125–2129.
6. Hirohara D, Nomura K, Okamoto T, Ujihara M, Takano K. Performance of the basal aldosterone to renin ratio and of the renin stimulation test by furosemide and upright posture in screening for aldosterone-producing adenoma in low renin hypertensives. J Clin Endocrinol Metab. 2001. 86:4292–4298.
7. Young WF Jr. Primary aldosteronism: A common and curable form of hypertension. Cardiol Rev. 1999. 7:207–214.
8. Holland OB, Brown H, Kuhnert L, Fairchild C, Risk M, Gomez-Sanchez CE. Further evaluation of saline infusion for the diagnosis of primary aldosteronism. Hypertension. 1984. 6:717–723.
9. Harper R, Ferrett CG, McKnight JA, McIlrath EM, Russell CF, Sheridan B, Atkinson AB. Accuracy of CT scanning and adrenal vein sampling in the pre-operative localization of aldosterone-secreting adrenal adenomas. QJM. 1999. 92:643–650.
10. Magill SB, Raff H, Shaker JL, Brickner RC, Knechtges TE, Kehoe ME, Findling JW. Comparison of adrenal vein sampling and computed tomography in the differentiation of primary aldosteronism. J Clin Endocrinol Metab. 2001. 86:1066–1071.
11. Kasper DL, Braunwald E, Fauci AS, Hauser SL, Longo DL, Jameson L, editors. Harrison's Principles of Internal Medicine. 2005. 16th ed. McGraw-Hill Companies;2138–2141.
12. Sasano H, Suzuki T, Moriya T. Recent advances in histopathology and immunohistochemistry of adrenocortical carcinoma. Endocr Pathol. 2006. 17:345–354.
13. DeLellis RA, Lloyd RV, Heitz PU, Eng C. World Health Organization classification of tumors. Pathology and genetics of tumors of endocrine organs. 2004. Lyon, France: IARC Press.
14. Allolio B, Hahner S, Weismann D, Fassnacht M. Management of adrenocortical carcinoma. Clin Endocrinol (Oxf). 2004. 60:273–287.
15. Gröndal S, Cedermark B, Eriksson B, Grimelius L, Harach R, Kristoffersson A, Rastad J, Udén P, Akerstöm G. Adrenocortical carcinoma. A retrospective study of a rare tumor with a poor prognosis. Eur J Surg Oncol. 1990. 16:500–506.
16. Wajchenberg BL, Albergaria Pereira MA, Medonca BB, Latronico AC, Campos Carneiro P, Alves VA, Zerbini MC, Liberman B, Carlos Gomes G, Kirschner MA. Adrenocortical carcinoma. clinical and laboratory observations. Cancer. 2000. 88:711–736.
17. Venkatesh S, Hickey RC, Sellin RV, Fernandez JF, Samaan NA. Adrenal cortical carcinoma. Cancer. 1989. 64:765–769.
18. Vassilopoulou-Sellin R, Schultz PN. Adrenocortical carcinoma. Clinical outcome at the end of the 20th century. Cancer. 2001. 92:1113–1121.
19. Terzolo M, Angeli A, Fassnacht M, Daffara F, Tauchmanova L, Conton PA, Rosseto R, Buci L, Sperone P, Grossrubatscher E, Reimondo G, Bollito E, Papotti M, Saeger W, Hahner S, Koschker AC, Arvat E, Ambrosi B, Loli P, Lombardi G, Mannelli M, Bruzzi P, Mantero F, Allolio B, Dogliotti L, Berruti A. Adjuvant mitotane treatment for adrenocortical carcinoma. N Engl J Med. 2007. 356:2372–2380.
20. Allolio B, Fassnacht M. Clinical review: Adrenocortical Carcinoma: Clinical Update. J Clin Endocrinol Metab. 2006. 91:2027–2037.
21. Stojadinovic A, Ghossein RA, Hoos A, Nissan A, Marshall D, Dudas M, Cordon-Cardo C, Jaques DP, Brennan MF. Adrenocortical carcinoma: clinical, morphologic, and molecular characterization. J Clin Oncol. 2002. 20:941–950.
XML Download